Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhNGF injection in healthy Chinese volunteers
NCT04232332Phase 1Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SQ-22031 in Optic neuropathies (10 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Incidence of adverse events at 34 days, Area under curve at 8 days and 3 more. Status: unknown.
02
Drugs
SQ-22031
03
Conditions
Optic neuropathies
Beyond the preview
Go deeper on NCT04232332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232332.